Anebulo Pharmaceuticals Q4 EPS $(0.10) Beats $(0.12) Estimate
Portfolio Pulse from Happy Mohamed
Anebulo Pharmaceuticals reported Q4 losses of $(0.10) per share, beating the analyst consensus estimate of $(0.12) by 16.67 percent. This is unchanged from the same period last year.
September 20, 2023 | 8:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Anebulo Pharmaceuticals' Q4 earnings per share beat analyst estimates by 16.67%, which could positively impact the stock in the short term.
Anebulo Pharmaceuticals reported better-than-expected Q4 earnings per share, which is often a positive signal to investors and can lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100